Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis

Dong Suwei1,2†, Xiao Yanbin2,4*, Wang Jianqiang1†, Ma Xiang2, Peng Zhuohui2, Kang Jianping2, Wang Yunqing1,4* and Li Zhen3,4*

Introduction
Cutaneous melanoma is the most aggressive skin cancer derived from melanocytes, accounting for 90% of skin-cancer-related deaths [1, 2] and about one-third of patients diagnosed with metastatic melanoma [3]. Although targeted therapy and immunotherapy has greatly improved objective response rate of patients with advanced melanoma [4], an important subset of patients with melanoma do not respond to these treatments or develop resistance over time [5]. Therefore, it is critical to identify the molecular mechanisms underlying melanoma metastasis.

Abstract
Melanoma is the most lethal skin cancer characterized by its high metastatic potential. It is urgent to find novel therapy strategies to overcome this feature. Metformin has been confirmed to suppress invasion and migration of various types of cancer. However, additional mechanisms underlying the antimetastatic effect of metformin on melanoma require further investigation. Here, we performed microarray analysis and uncovered an altered mRNA and miRNA expression profile between melanoma and nevus. Luciferase reporter assay confirmed that miR-5100 targets SPINK5 to activate STAT3 phosphorylation. Migration and wound healing assays showed that the miR-5100/SPINK5/STAT3 axis promotes melanoma cell metastasis; the mechanism was proven by initiation of epithelial–mesenchymal transition. Co-immunoprecipitation (Co-IP) further confirmed an indirect interaction between SPINK5 and STAT3. Furthermore, metformin dramatically inhibited miR-5100/SPINK5/STAT3 pathway, and decreased B16-F10 cell metastasis to lung in C57 mouse module. Intriguingly, pretreatment of metformin before melanoma cell injection improved this effect further. These findings exposed the underlying mechanisms of action of metformin and update the use of this drug to prevent metastasis in melanoma.

Keywords: EMT, miR-5100, Metformin, SPINK5, STAT3
concomitantly, enabling the cells to acquire motile and invasive features to become mesenchymal cells [7].

MicroRNAs (miRNAs/miRs) are small noncoding RNAs that regulate target genes by recognizing a complementary mRNA sequence and subsequently repressing its translation [8]. A growing number of studies have uncovered the key regulatory role of miRNAs in cancer metastasis [9–11]. On the basis of miRNA assay, we found that miR-5100 expression is increased in melanoma. Moreover, expression profile microarray revealed that serine peptidase inhibitor Kazal type 5 (SPINK5) is decreased in melanoma. SPINK5, a member of the serine protease inhibitor family, has been considered as a tumor suppressor [12, 13]. It is expressed in the stratified epithelial tissues of the skin, and inhibition of SPINK5 leads to enhanced activity of serine protease [14]. Signal transducer and activator of transcription 3 (STAT3) is a critical transcription factor [15]. Studies have suggested that p-STAT3 (Try 705), as the activated form, modulates cancer EMT signals [16], which could be activated by serine proteases [17, 18]. Thus, we suspect that miR-5100 targets SPINK5 and, consequently, activates STAT3.

Metformin (1,1-dimethylbiguanide hydrochloride), a commonly used drug to treat type 2 diabetes, has been found to be associated with a decreased incidence and mortality in several cancers [19]. Moreover, it showed antimetastatic effects in a variety of cancer cells [20]. However, the effect of metformin administration on the EMT process in melanoma has yet to be illuminated.

In the present study, we demonstrated the effects of metformin on the EMT process in melanoma cells. The results showed that metformin inhibited the melanoma EMT process by modulating the miR-5100/SPINK5/STAT3 signaling pathway, suggesting the potential of metformin to serve as an effective antimetastatic drug for melanoma.

**Materials and methods**

**Human tissues**

Ten formalin-fixed and paraffin-embedded (FFPE) melanoma and nevus samples (five of each) were used for microarrays. For immunohistochemistry staining, we collected another 47 melanoma and 56 nevus tissues from the Third Affiliated Hospital of Kunming Medical University between 2012 and 2018. Of the 47 melanoma and 56 nevus tissues, 18 samples of each group acquired qualified RNA for RT-PCR. All patients received no chemotherapy, radiotherapy, or biotherapy before operation to avoid changes in protein expression resulting from treatment. This study protocol was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Kunming Medical University. Written informed consent was obtained from all patients. The procedures for the collection and use of tissues were performed in accordance with the guidelines of the Declaration of Helsinki, 2013.

**miRNA and mRNA microarray expression analysis**

The RecoverAll Total RNA Isolation Kit (Ambion, Canada) was used to extract total RNA (including miRNA) from ten paraffin-embedded melanoma and nevus specimens. Differentially expressed miRNAs were detected using the Agilent Human miRNA Microarray (Agilent V16.0). mRNA expression was detected by Affymetrix microarrays (Affymetrix Almac Xcel Array). Fold change ≥ 2 or ≤ 0.5 was considered as significantly
differential expression. The microarray data presented in the present study are available online at the Gene Expression Omnibus of the National Center for Biotechnology Information (NCBI). (https://www.ncbi.nlm.nih.gov/geo/; accession no. GSE183115, GSE183116.

Cell culture and transfection
293T, human melanoma cell line A2058, G361 and murine melanoma cell line B16-F10 were obtained from the ATCC. The cells were cultured in DMEM medium (Gibco, USA) containing 10% FBS (Gibco, USA). Cells were incubated at 37 °C with 5% CO₂. siRNA and expression vectors (RiboBio, China) using Lipofectamine® 2000 reagent (Invitrogen, USA) at a final concentration of 50 nM, according to the manufacturer’s instructions. A total of 48 h after transfection, cells were collected for the further experiments. The IC₅₀ values were determined as previously reported [21].

Extraction of RNA and quantitative RT-PCR
Eighteen samples of melanoma and nevus group were employed for RT-PCR (not including samples for microarray test). Total RNA was extracted from cells by using TRIzol (Invitrogen, USA) method according to the kit’s technical manual. Total RNA of the cell was converted into cDNA with miScript Reverse Transcription Kit (Qiagen GmbH), then expression analyses were performed by Roche Lightcycler 480 Real-Time PCR system (Roche Diagnostics, Switzerland) according to the predetermined conditions. Primer sequences and samples clinical parameters are shown in Additional file 1: Data S1. The results were analyzed using the 2⁻△ΔCt method [22]. All samples were analyzed at least in triplicate.

Western blot analysis
The protein samples were extracted from the cells and tissue was extracted using RIPA buffer (Pierce, USA) and quantitatively measured with a BCA Protein Assay Kit (Thermo, USA). Western blotting was conducted as previously described [23]. Antibodies against SPINK5 (ab138511), STAT3 (ab68153), p-STAT3-Y705 (ab267373), E-cadherin (ab1416), N-cadherin (ab76011), Snail (ab216347), Vimentin (ab92547), and GAPDH (ab181602) were purchased from Abcam (Cambridgeshire, UK).

Luciferase reporter assay
Melanoma cells were cotransfected with pGL3-basic luciferase reporter vector (wild type or mutant), miR-5100 mimic, or the control. After 48 h of transfection, luciferase assay was performed using the Dual Luciferase Reporter Assay System (Promega, USA) according to the manufacturer’s instructions.

Wound-healing assays
The cells were seeded into six-well plates, and the wound was scratched by plastic tips when a monolayer formed. To remove the detached cells and debris, the main cells were washed by PBS. The size of the wounds was measured at different timepoints. The experiments were performed at least three times.
Transwell assays
Transwell migration assays were performed using transwell migration chambers (8.0 µm pore inserts, BD Biosciences, USA). A total of \(3 \times 10^5\) cells with DMEM without FBS were seeded into the inner chamber, and DMEM medium with 10% FBS was added to the bottom chambers as an attractant. After 24 h of incubation, migratory cells on the lower surface were stained with 0.1% crystal violet solution (Sigma-Aldrich, USA), and colonies were counted immediately.

Immunofluorescent staining
Cells were seeded in six-well plate, after washing with PBS and fixation with 4% paraformaldehyde. Then, the cells were permeabilized with 0.5% Triton X-100, and blocked in 10% goat serum at room temperature. Primary antibodies were incubated overnight, and the next day, cells were incubated with fluorescent secondary antibodies. Then, we imaged the nuclei of DAPI-labeled cells by confocal fluorescence microscopy (Nikon A1, Japan).

Co-immunoprecipitation (Co-IP)
293T cells were collected and lysed using RIPA Lysis Buffer (Pierce, USA). Then, protein A/G beads (Santa Cruz, USA) were co-incubated with the primary antibody or IgG at 4 °C for 6 h. Cell lysate was added to the mixture of beads and antibody overnight at 4 °C. The beads–antibody–protein complexes were washed with precooled PBS solution three times (each time for 10 min). Finally, samples were detected by western blot analysis.

Hematoxylin–eosin (HE) and immunohistochemistry (IHC) staining
For HE staining, sections were subjected to hematoxylin and eosin staining and observed with a light microscope (Leica, Japan). The representative images were taken by fluorescence microscope. Paraffin-embedded tissue sections were stained with an antibody against SPINK5 (Abcam, ab138511, USA), the slides were incubated with ABC (Vector Laboratories, USA) and overlaid with 3-30-diaminobenzidine (DAB; Dako, USA), and the nuclei were stained with hematoxylin, following a previously described method [21]. The slides were viewed using a BZ9000 microscope (Zeiss, Germany).

In vivo tumor metastasis assay
Six- to eight-week-old SPF female C57BL/6 mice were purchased from the Beijing Laboratory Animal Center (Beijing, China) and randomly divided into three groups: (A) control group \((n=5)\), mice were treated with PBS after B16-F10 cell injection; (B) metformin treatment group, to measure the therapy function, mice were treated by 3 mg/kg of metformin for 14 days (intraperitoneally) after cell injection; (C) metformin prevent and treatment group, to evaluate the chemopreventive effects, mice were treated by 3 mg/kg of metformin for 7 days before and 14 days after cell injection. To establish a murine melanoma pulmonary metastasis model, \(4 \times 10^5\) B16-F10 cells were injected via the tail vein. Two weeks later, mice were sacrificed and lungs were carefully harvested, the tissues were fixed in a neutral-buffered formaldehyde solution, and the metastasis
foci were counted as black or white forms on the tissue surface. This study was approved by the Experimental Animal Ethics Committee of the Third Affiliated Hospital of Kunming Medical University.

Statistics
Data are presented as mean ± standard deviation (SD). SPSS for Windows version 18.0 (SPSS Inc., Chicago, IL, USA) was used for \( \chi^2 \) test and Student’s \( t \)-test. A \( p \)-value < 0.05 was considered significant.

Results
miR-5100 modulates melanoma EMT process
To identify miRNA and mRNA differently expressed between melanoma and nevus, miRNA and mRNA expression microarray were employed (GSE183115, GSE183116), of which miR-5100 expression exhibited elevation in melanoma by qPCR (\( p < 0.001 \), Fig. 1A). On the contrary, IHC showed a lower expression of SPINK5 in melanoma (Fig. 1B, Tables 1, 2). Moreover, TargetScan (http://www.targetscan.org/) uncovered that SPINK5 is a potential target of miR-5100, and western blotting showed that the miR-5100 mimic decreased SPINK5 expression and the miR-5100 inhibitor elicited the opposite effect (Fig. 1C). Dual-luciferase reporter assays revealed that miR-5100 overexpression decreased the luciferase activity of pGL3-SPINK5-Wt but not that of pGL3-SPINK5-Mut (Fig. 1D). Furthermore, TCGA data revealed an increased expression of miR-5100 in metastatic melanoma, whereas SPINK5 exhibited the opposite trend by online bioinformatics analysis (http://ualcan.path.uab.edu/, data from TCGA, Additional file 2: Data S2).

We then investigated the effect of miR-5100 on melanoma cell metastasis. Following transfection of melanoma cells with the miR-5100 mimic or inhibitor, wound-healing and transwell assays showed that miR-5100 mimic caused an obvious increase in migration cells of A2058 and G361 compared with the control group, while miR-5100 inhibitor had the opposite effect (Fig. 1E, F).

We next focused on identifying a mechanistic basis for how miR-5100 promotes a metastatic phenotype. Studies have reported that EMT has implications for tumor cell metastasis by triggering the loss of cell–cell adhesion [24]. The levels of EMT makers were examined by western blot. The expression of epithelial marker E-cadherin was decreased while mesenchymal markers N-cadherin, Snail, and Vimentin expression levels increased after miR-5100 mimic transfection; meanwhile, the opposite result was observed after the interference of miR-5100 inhibitor (Fig. 1G).

It has been shown that the initiation of EMT was mostly modulated by STAT3 activation [25]. In this study, miR-5100 mimic promoted STAT3 expression and phosphorylation at tyrosine 705 (Fig. 1H, I). These data suggest that miR-5100 modulates melanoma EMT probably via the SPINK5–STAT3 pathway.

SPINK5–STAT3 pathway modulates melanoma EMT process
To explore the functions of SPINK5 in melanoma cells, its effects on the migration of A2058 and G361 cells was examined. We found that knockdown of SPINK5 apparently elevated the metastasis ability of melanoma cells. Conversely, SPINK5 expression
miR-5100 modulates melanoma cell EMT by targeting SPINK5–STAT3 pathway. 

A, B Expression of miR-5100 and SPINK5 was measured by RT-qPCR and IHC in melanoma and nevus specimens. C, D The miR-5100 binding site in the 3′-UTR of SPINK5 and matched mutations; miR-5100 modulates SPINK5 expression. Furthermore, a luciferase reporter assay was conducted in 293T cells to verify the interaction between miR-5100 and the SPINK5 binding site. E, F The metastasis inhibition effects of miR-5100 were measured by wound-healing and transwell assays. G miR-5100 modulates melanoma cell EMT process shown by EMT-related markers determined by western blot analysis. H, I Immunoblotting and IF analysis of STAT3, and phosphorylation of STAT3 in A2058 and G361 cell lines transfected with either a mimic or an inhibitor of miR-5100. *p < 0.05, **p < 0.01, ***p < 0.001 versus control.
inhibited cells’ metastasis capacity (Fig. 2A–C). In line with the cell motility change, knockdown of SPINK5 decreased E-cadherin protein expression but increased mesenchymal markers. As expected, SPINK5 overexpression induced a mesenchymal–epithelial transition phenotype (Fig. 2D).

STAT3 is one of the pivotal proteins involved in the EMT process. The present study uncovered that SPINK5 knockdown induced STAT3 phosphorylation and nucleus location, and contrary findings were observed after SPINK5 expression vector transfection.
Moreover, after cotransfection, we performed Co-IP assay to verify the interaction between SPINK5 and STAT3. IgG (negative control) blocked the antigen–antibody binding reaction. In the input (positive control), we detected STAT3 and SPINK5 by western blot, but in the IP group only STAT3 was detected. These findings confirm that SPINK5 cannot interact with STAT3 (Fig. 2G, H) and indicate that SPINK5 modulates melanoma EMT by STAT3, indirectly.

### Table 1. Clinicopathologic characteristics of patients with melanoma

| Clinicopathologic characteristics | Number of samples (%) |
|----------------------------------|-----------------------|
| Age, years                       |                       |
| < 50                             | 18 (38.30)            |
| ≥ 50                             | 29 (61.70)            |
| Gender                           |                       |
| Male                             | 30 (63.83)            |
| Female                           | 17 (36.17)            |
| Ulceration                       |                       |
| Positive                         | 23 (69.70)            |
| Negative                         | 10 (21.28)            |
| Lymph node metastasis            |                       |
| Positive                         | 17 (36.17)            |
| Negative                         | 18 (38.30)            |
| Pathologic grade                 |                       |
| I                                | 10 (25.00)            |
| II                               | 13 (32.50)            |
| III                              | 14 (35.00)            |
| IV                               | 3 (7.50)              |

### Table 2. Expression of SPINK5 in melanoma and nevus specimens

| Disease       | Total | SPINK5 | p   |
|---------------|-------|--------|-----|
|               |       | Positive (%) | Negative (%) |
| Melanoma      | 47    | 16 (34.04)    | 31 (65.96)  | 0.001 |
| Nevus         | 56    | 38 (67.86)    | 18 (32.14)  |      |

*p < 0.05, statistically significant difference*

(Fig. 2E, F). Moreover, after cotransfection, we performed Co-IP assay to verify the interaction between SPINK5 and STAT3. IgG (negative control) blocked the antigen–antibody binding reaction. In the input (positive control), we detected STAT3 and SPINK5 by western blot, but in the IP group only STAT3 was detected. These findings confirm that SPINK5 cannot interact with STAT3 (Fig. 2G, H) and indicate that SPINK5 modulates melanoma EMT by STAT3, indirectly.

Metformin inhibits EMT by regulating the miR-5100/SPINK5/STAT3 axis

The antitumor activity toward melanoma cells was evaluated for metformin. IC\textsubscript{50} values were obtained from the MTT assay. In this experiment, metformin exhibited IC\textsubscript{50} values of 16.61 and 15.10 mM for A2058 and G361 cells, respectively, at 48 h (Fig. 3A). On the basis of the IC\textsubscript{50} results, the antimetastatic effect of metformin on melanoma cells was examined by wound-healing and transwell assays. As demonstrated, metformin significantly inhibited the motility of the melanoma cells (Fig. 3B, C). Meanwhile, metformin treatment reduced mesenchymal cell markers, including Snail, Vimentin, and N-cadherin, but restored E-cadherin expression (Fig. 3D), indicating that metformin inhibited migration of melanoma cells by reversing the EMT process.
Fig. 2  SPINK5 modulates melanoma cells EMT by STAT3 phosphorylation. A Western blot and RT-qPCR were used to detect SPINK5 expression after transfection with either an siRNA or an expression vector. B, C Wound-healing and transwell assays were used to determine the effects of SPINK5 in melanoma cell metastasis. D SPINK5 modulates melanoma cell EMT process shown by EMT-related markers determined by western blot analysis. E, F Immunoblotting and IF analysis of STAT3, and the phosphorylation of STAT3 in A2058 and G361 cell lines transfected with either a SPINK5 siRNA or expression vector. G, H After cotransfection, Co-IP was used to measure the interaction between SPINK5 and STAT3 in 293T cells. *p < 0.05, **p < 0.01, ***p < 0.001 versus control
Then, to explore the potential mechanism by which metformin mediated inhibition of the metastasis of melanoma cells, the expression of miR-5100, SPINK5, and STAT3 was detected after treatment with metformin for 48 h. As shown, metformin inhibited expression of miR-5100 and pSTAT3 but upregulated SPINK5 (Fig. 3D, E). Moreover, miR-5100 mimic neutralized the inhibitory effect of metformin on cell metastasis and EMT process partly (Fig. 3F–H).

These data indicate that metformin suppressed melanoma cell migration by regulating the miR-5100/SPINK5/STAT3 axis.

Metformin inhibits melanoma cells metastasis in vivo

To corroborate our in vitro results, C57 mice were injected with B16F10 cells (1.0 × 10⁶ cells per mouse) into the tail vein. To confirm that metformin served as a metastasis inhibitor for B16F10 tumor cells, 14 days after melanoma cell injection, all mice were sacrificed and lung was removed to count the metastasis foci. Moreover, we treated mice with metformin before B16F10 injection (Fig. 4A). Notably, we found that metformin restored the metastatic capacity of B16F10. Interestingly, metformin pre-treatment improved this effect further (Fig. 4B).

Discussion

On the basis of high-throughput microarray technology, we acquired amount of differently expressed miRNAs. In the present study, we focused on molecules participating in melanoma metastasis regulation. Integrating our results with TCGA data, we found that miR-5100 expression was upregulated in melanoma tissues. In concordance with previous studies [26, 27], our results demonstrated that miR-5100 could modulate melanoma cells’ EMT process. miRNA could regulate many different target mRNAs, according to our microarray results and TCGA database, and we uncovered that SPINK5 expression is opposite to that of miR5100. Furthermore, TargetScan also indicated a regulative...
relation between these two molecules. In this study we confirmed that SPINK5 served as a direct target of miR-5100.

SPINK5, a serine protease inhibitor that contains 15 Kazal-type serine protease inhibitory domains [28], has been considered as a tumor suppressor in various cancers [29, 30]. Moreover, SPINK5 was considered as marker for prediction of lymph node metastasis in HNSCC [31]. Herein, we found that SPINK5 was remarkably
decreased in melanoma compared with nevus tissues, suggesting that SPINK5 may be a potential tumor suppressor in melanoma. Furthermore, silencing of SPINK5 prominently increased the metastasis abilities of melanoma cells, whereas SPINK5 overexpression exhibited the opposite trend. These were further confirmed by measurement of EMT markers. Thus, our data suggest that SPINK5 inhibits melanoma cells motility by modulating the EMT process.

EMT is considered to be a critical event in cancer cell migration, which is driven by the STAT3 pathway [32]. STAT3 activity is dependent on two phosphorylation sites: phosphorylation of tyrosine 705 (Try 705) and serine 727 (Ser 727). Recently, a study
revealed that the pY705–STAT3 pathway elicits EMT and pS727–STAT3 signaling induces MET process [16].

Mechanistically, activated Janus kinase (JAK) leads to an increase in STAT3 phosphorylation at Y705 [33]. It has been confirmed that expression of Kallikrein-related peptidases (KLKs) could induce the activation of JAK [34]. KLKs constitute a large family of secreted trypsin and chymotrypsin-like serine proteinases that are expressed in multiple tissues [35]. However, this process is inhibited by SPINK5 directly [36]. In concordance with this, our results confirmed that SPINK5 expression inhibited STAT3 Tyr705 phosphorylation. Disappointingly, Co-IP demonstrated an indirect interaction between SPINK5 and STAT3. Thus, further study is required to uncover the underlying modulation mechanisms between SPINK5 and STAT3.

Metformin has been revealed to serve as a potent antitumor drug for the treatment of multiple cancers, including melanoma [21, 37–39]. Some cohort studies have shown that metformin suppresses the invasion and migration of various types of cancer [40, 41]. Researchers have documented that metformin blocks melanoma cell invasion and metastasis through AMPK activation [42], which decreases cancer cell mTOR signaling and protein synthesis [43]. We have proven that metformin could inhibit the proliferation and stemness of NSCLC [21]. Moreover, studies have uncovered that melanoma cell growth and motility were hampered by metformin treatment through modulation of various microRNA expression [44]. However, the underlying antimitastatic mechanism of metformin on the regulation of miRNAs in melanoma remains unclear. Thus, we employed metformin to measure its antimitastatic function. We show here that metformin treatment inhibited melanoma cell migration and EMT process. Notably,
metformin suppressed miR-5100 but elevated SPINK5 expression, importantly, which inhibited STAT3 expression and Tyr705 phosphorylation. However, the underlying mechanisms by which metformin modulates miR-5100 expression remain to be discussed.

Studies have shown that patients with diabetes who had taken metformin had a reduction of incidence and mortality of various cancers [38, 39, 45]. Moreover, it is reported that metformin could reduce the risk of metastasis in breast cancer [46, 47]. Consistently, our in vivo study showed that metformin suppressed melanoma cell metastasis. More importantly, metformin pretreatment abolished the pulmonary metastasis of B16-F10 cells. We suspect metformin pretreatment not only impacts intracellular pathways to inhibit metastasis, but also modulates the extracellular microenvironment, e.g., adhesion molecules [48], vascular leakiness [49], and extracellular matrix remodeling [49] in distant organs. Of note, metformin also led to the activation of antitumor immune and metabolic reprogramming in both lab experiments and clinical trials [50–53]. Thus, metformin pretreatment reinforced these effects and showed fewer metastasis foci.

As the metastasis foci are too tiny and scattered to be collected for further study, we failed to provide in vivo evidence that metformin modulates miR-5100, SPINK5, STAT3, and EMT protein expression. However, studies have uncovered that metformin reduced the number of metastases in animal models [41]. Moreover, it has been confirmed that metformin could inhibit EMT protein expression in a xenograft mouse model bearing tumors [54], decrease the circulating tumor cell (CTC) adhesion to activated endothelial cells, and alleviate lung vascular permeability [55]. These findings provide indirect evidence that metformin inhibits lung metastasis by modulating the EMT process in our in vivo model.

In summary, metformin suppressed melanoma cell migration and EMT. Moreover, this effect is partly dependent on the miR-5100/SPINK5/STAT3 pathway, indicating that metformin is a potential oncotherapeutic agent. These findings may provide a possible strategy for the clinical treatment of melanoma.

**Availability of data**

We declare that the materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for noncommercial purposes, without breaching participant confidentiality.

**Abbreviations**

- EMT: Epithelial–mesenchymal transition
- SPINK5: Serine peptidase inhibitor Kazal type 5
- STAT3: Signal transducer and activator of transcription 3
- RT-PCR: Quantitative polymerase chain reaction
- Co-IP: Co-immunoprecipitation
- HE: Hematoxylin–eosin
- IHC: Immunohistochemistry

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s11658-022-00353-5](https://doi.org/10.1186/s11658-022-00353-5).

**Additional file 1: Data S1.** Primer sequences for RT-qPCR. Clinicopathologic characteristics of melanoma and nevus patients.
Additional file 2. Data S2. TCGA data showed the expression patterns of miR-5100 and SPINK5 in normal tissue, primary melanoma and metastatic melanoma.

Acknowledgements
Not applicable.

Author contributions
L.Z., W.Y., and W.J. supervised the study and edited the manuscript. D.S. and X.Y. conducted this study and drafted the manuscript. M.X. performed the tissue test and statistical analysis. P.Z. and K.J. carried out all experiments. D.S., X.Y., and W.J. contribute equally to the work. All authors read and approved the final manuscript.

Funding
This study was supported in part by grants from the National Natural Science Foundation of China (#81760495), Basic Research Program of Xuzhou Health Commission (KC21060, KC21049) and Development Foundation of Affiliated hospital of Xuzhou Medical University (XYFY2020001, XYFY2020002).

Declarations

Ethics approval and consent to participate
This study protocol was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Kunming Medical University. The procedures for the collection and use of tissues were performed in accordance with the guidelines of the Helsinki Declaration of 2013 (no. 2016-16, 2 March 2017, for both patients and animals).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 10 February 2022   Accepted: 31 May 2022
Published online: 15 June 2022

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017. https://doi.org/10.3322/caac.21387.
2. Dimitriou F, Krattinger R, Rameytle E, Barysch MJ, Micaletto S, Dummer R, et al. The world of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the globe. Curr Oncol Rep. 2018. https://doi.org/10.1007/s11912-018-0732-8.
3. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011;11:85. https://doi.org/10.1186/1471-2407-11-85.
4. Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017;44(2):132–5. https://doi.org/10.1053/j.semincancer.2017.06.007.
5. Olino K, Park T, Ahuja N. Exposing hidden targets: combining epigenetic and immunotherapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:114–22. https://doi.org/10.1016/j.semcancer.2020.01.001.
6. Xiao D, Barry S, Kmetz D, Egger M, Pan J, Rai SN, et al. Melanoma cell-derived exosomes promote epithelial−mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. Cancer Lett. 2016;376(2):318–27. https://doi.org/10.1016/j.canlet.2016.03.050.
7. Wendt MK, Taylor MA, Schemmann BJ, Schemmann WP. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell. 2011;22(14):2423–35. https://doi.org/10.1091/mbc.E11-04-0306.
8. Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015. https://doi.org/10.1126/scisignal.2005825.
9. Weidle UH, AusAnder S, Brinkmann U. Micro RNAs promoting growth and metastasis in preclinical in vivo models of subcutaneous melanoma. Cancer Genomics Proteomics. 2020;17(6):651–67. https://doi.org/10.21873/cgp.20221.
10. Fomeshi MR, Ebrahimi M, Mowla SJ, Khosravani F, Firoozi J, Khayatzadeh H. Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells. Cell Mol Biol Lett. 2015;20(3):448–65. https://doi.org/10.1515/cmb-2015-0025.
11. Chen M, Chen C, Luo H, Ren J, Dai Q, Hu W, et al. MicroRNA-296–5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial−mesenchymal transition. Cell Mol Biol Lett. 2020;25:49. https://doi.org/10.18116/s11658-020-00240-x.
12. Wang Q, Lv Q, Bian H, Yang L, Guo KL, Ye SS, et al. A novel tumor suppressor SPINK5 targets Wnt/β-catenin signaling pathway in esophageal cancer. Cancer Med. 2019;8(5):2360–71. https://doi.org/10.1002/cam4.2078.
13. Lv Z, Wu K, Qin X, Yuan J, Yan M, Zhang J, et al. A novel tumor suppressor SPINK5 serves as an independent prognostic predictor for patients with head and neck squamous cell carcinoma. Cancer Manag Res. 2020;12:4855–69. https://doi.org/10.2147/cmar.s236066.
et al. Cellular & Molecular Biology Letters           (2022) 27:48

14. Komatsu N, Takata M, Otsuki N, Ohka R, Amano O, Takehara K, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINKS-derived peptides. J Invest Dermatol. 2002;118(3):436–43. https://doi.org/10.1046/j.1523-1747.2001.01663.x.

15. Galcovsza M, Coates P, Voitek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 2018;23:12. https://doi.org/10.1080/11656817.2018.0978-0.

16. Lin WH, Chang YW, Hong MX, Hsu TC, Lee KC, Lin C, et al. STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT–MET switch and cancer metastasis. Oncogene. 2021;40(4):791–805. https://doi.org/10.1038/s41388-020-01566-8.

17. Watkiss MS, Chandrasekharan UM, Willard B, Haque SJ, DiCorleto PE. STAT3-mediated coincidence detection regulates noncanonical immediate early gene induction. J Biol Chem. 2013;288(17):11988–2003. https://doi.org/10.1074/jbc.M112-428516.

18. Smith CC, Dixon RA, Wynne AM, Theodoulou L, Ong SG, Subrayan S, et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol. 2010;299(4):H1265–70. https://doi.org/10.1152/ajpheart.00092.2010.

19. Drzewoski J, Hanefeld M. The current and potential therapeutic use of metformin—the good old drug. Pharmaceutics (Basel, Switzerland). 2021;13:42. https://doi.org/10.3390/ph13020022.

20. Chen YC, Li H, Wang J. Mechanisms of metformin inhibiting cancer invasion and migration. Am J Transl Res. 2020;12(9):4885–901.

21. Suwei D, Liang Z, Zhimin L, Ruilei L, Yingying Z, Zhen L, et al. NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin. J Hematol Oncol. 2015;8:120. https://doi.org/10.1186/s13045-015-0203-8.

22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔCT) Method. Methods. (San Diego, Calif.) 2001;25(4):402–8. https://doi.org/10.1016/S1046-2023(00)00667-9.

23. Dong S, Xiao Y, Ma X, He W, Kang J, Peng Z, et al. miR-193b increases the chemosensitivity of osteosarcoma cells by promoting FEN-1-mediated autophagy. Onco Targets Ther. 2019;12:10089–98. https://doi.org/10.2147/ott.s219977.

24. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013;24(4):466–80. https://doi.org/10.1016/j.ccr.2013.08.018.

25. Jin W. Role of JAK/STAT3 signaling in the regulation of metastasis, the transition of cancer stem cells, and chemoreistance of cancer by epithelial–mesenchymal transition. Cells. 2020;9:1. https://doi.org/10.3390/cells9010027.

26. Wei Z, Lyu B, Hou D, Liu X. Mir-5100 mediates proliferation, migration and invasion of oral squamous cell carcinoma cells via targeting SCAS/C. J Invest Surg. 2021;34(8):834–41. https://doi.org/10.1080/08941939.2019.1701754.

27. Li CY, Wang YH, Lin ZY, Yang LW, Gao SL, Liu T, et al. Mir-5100 targets TOB2 to drive epithelial–mesenchymal transition associated with activating smad2/3 in lung epithelial cells. Am J Transl Res. 2017;9(10):4694–706.

28. Roedl D, Oji V, Buters JT, Behrendt H, Braun-Falco M. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. JAMA Intern Med. 2020;180(9):1198–7.

29. Li RG, Deng H, Liu XH, Chen ZY, Wan SS, Wang L. Histone methyltransferase G9a promotes the development of renal cancer through epigenetic silencing of tumor suppressor gene SPINKS. Oxid Med Cell Longev. 2021;2021:6650781. https://doi.org/10.1155/2021/6650781.

30. Alves MG, Kodama MH, da Silva EZM, Gomes BMM, da Silva RAA, Vieira GV, et al. Relative expression of KLK5 to LEKTI is associated with aggressiveness of oral squamous cell carcinoma. Transl Oncol. 2021. https://doi.org/10.1016/j.tranon.2020.100970.

31. van Hooff SR, Leusink FK, Roeperman P, Baatenburg de Jong RJ, Speel EJ, van den Brekel MW, et al. Validation of a gene expression signature for assessment of lymph node metastasis in oral squamous cell carcinoma. J Clin Oncol. 2012. https://doi.org/10.1200/jco.2011.40.4509.

32. Liu W, Huang G, Yang Y, Gao R, Zhang S, Kou B. Oridonin inhibits epithelial–mesenchymal transition of human naso- tranon. 2020. 100970.

33. Kaptein A, Paillard V, Saunders M. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem. 1996;271(11):5961–4. https://doi.org/10.1074/jbc.271.11.5961.

34. Yasuda T, Fukada T, Kishida K, Nakayama M, Matsuda M, Miura I, et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J Clin Investig. 2016;126(6):2064–76. https://doi.org/10.1172/jci82887.

35. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32. https://doi.org/10.1373/clinchem.2007.088104.

36. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9):3607–19. https://doi.org/10.1091/mbc.e07-02-0124.

37. Lee Y, Park D. Effect of metformin in combination with trtametinib and paclitaxel on cell survival and metastasis in melanoma cells. Anticancer Res. 2021;41(3):1387–99. https://doi.org/10.21873/anticancer.14896.

38. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ (Clin Res Ed). 2005;330(7503):1304–5. https://doi.org/10.1136/bmj.38415.708634.F7.

39. Baur DM, Klotsche J, Hamnvik OP, Pieper L, Wittchen HU, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011. https://doi.org/10.1016/j.metabol.2010.09.012.

40. Farahi A, Abedini MR, Javdani H, Arzi L, Chamani E, Farhoudi R, et al. Crocin and metformin suppress metastatic breast cancer progression via VEGF and MMP9 downregulations: in vitro and in vivo studies. Mol Cell Biochem. 2021. https://doi.org/10.1007/s11010-020-04043-8.

41. Kawakita E, Yang F, Kumagai A, Takagi Y, Kitaeda M, Yoshitomi Y, et al. Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling. Mol Cancer Res. 2021;19(1):61–73. https://doi.org/10.1158/1541-7786.MCR-20-0115.
42. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther. 2013;12(8):1605–15. https://doi.org/10.1158/1535-7163.Mct-12-1226-t.

43. Okubo K, Isono M, Asano T, Sato A. Metformin augments panobinostat's anti-bladder cancer activity by activating AMP-activated protein kinase. Transl Oncol. 2019;12(9):669–92. https://doi.org/10.1016/j.tranon.2019.02.001.

44. Tseng HW, Li SC, Tsai KW. Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression. Cancers. 2019;11:2. https://doi.org/10.3390/cancers11020209.

45. Kang J, Jeong SM, Shin DW, Cho M, Cho JH, Kim J. The associations of aspirin, statins, and metformin with lung cancer risk and related mortality: a time-dependent analysis of population-based nationally representative data. J Thorac Oncol. 2021;16(1):76–88. https://doi.org/10.1016/j.jtho.2020.08.021.

46. Jacob L, Kostev K, Rathmann W, Kalder M. Impact of metformin on metastases in patients with breast cancer and type 2 diabetes. J Diabetes Complications. 2016;30(6):1056–9. https://doi.org/10.1016/j.jdiacomp.2016.04.003.

47. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118(S):1202–11. https://doi.org/10.1002/cncr.26439.

48. Witkowski M, Friebel J, Tabarbie T, Grabitz S, Dörner A, Taghipour L, et al. Metformin is associated with reduced tissue factor procoagulant activity in patients with poorly controlled diabetes. Cardiovasc Drugs Ther. 2021;35(4):809–13. https://doi.org/10.1007/s10557-020-07040-7.

49. Wang JC, Li GY, Wang B, Han SX, Sun X, Jiang YN, et al. Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation. J Exp Clin Cancer Res. 2019;38:235. https://doi.org/10.1186/s13046-019-1211-2.

50. Veeramachaneni R, Yu W, Newton JM, Kemnade JO, Skinner HD, Sikora AG, et al. Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects. J Immunother Cancer. 2021;9:7. https://doi.org/10.1136/jitc-2021-002773.

51. Chou PC, Choi HH, Huang Y, Fuentes-Matti E, Velazquez-Torres G, Zhang F, et al. Impact of diabetes on promoting the growth of breast cancer. Cancer Commun (London, England). 2021;41(5):414–31. https://doi.org/10.1002/cac2.12147.

52. Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res. 2020;26(18):4921–32. https://doi.org/10.1158/1078-0432.Ccr-20-0113.

53. Pusceddu S, Vernieri C, Prinzi N, Torchio M, Coppa J, Antista M, et al. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. Ther Adv Gastroenterol. 2020;13:175628482092727.1. https://doi.org/10.1177/1756284820927271.

54. Deng T, Shen P, Li A, Zhang Z, Yang H, Deng X, et al. CCDC65 as a new potential tumor suppressor induced by metformin inhibits activation of AKT1 via ubiquitination of ENO1 in gastric cancer. Theranostics. 2021;11(16):8112–28. https://doi.org/10.7150/thno.54961.

55. Jiang T, Chen L, Huang Y, Wang J, Xu M, Zhou S, et al. Metformin and docosahexaenoic acid hybrid micelles for premetastatic niche modulation and tumor metastasis suppression. Nano Lett. 2019;19(6):3548–62. https://doi.org/10.1021/acs.nanolett.9b00495.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.